Natural History of Southeast Asian Chronic Myeloid Leukemia Patients with Different BCR-ABL Gene Variants

2006 ◽  
Vol 116 (2) ◽  
pp. 114-119 ◽  
Author(s):  
C.U. Auewarakul ◽  
S. Huang ◽  
M. Yimyam ◽  
S. Boonmoh
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Southeast Asian ◽  
Gene Variants ◽  
History Of

scholarly journals The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

2019 ◽  
Vol 3 (7) ◽  
pp. 1084-1091 ◽  
Author(s):  
Adrian G. Minson ◽  
Katherine Cummins ◽  
Lucy Fox ◽  
Ben Costello ◽  
David Yeung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Molecular Response ◽  
Increased Risk ◽  
History Of ◽  
Dose Modifications

Abstract Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overall, AEs of any grade were reported in 95 patients (43%) and prompted nilotinib cessation in 46 (21%). VAEs occurred in 26 patients (12%), with an incidence of 4.1 events per 100 patient-years. Multivariate analysis identified age (P = .022) and dyslipidemia (P = .007) as independent variables for their development. There was 1 fatal first VAE, whereas the remaining patients either continued nilotinib (14 patients) or stopped it immediately (11 patients). Recurrent VAEs were associated with ongoing therapy in 7 of 14 who continued (with 2 fatal VAEs) vs 1 of 11 who discontinued (P = .04). Nineteen of the 23 evaluable patients surviving a VAE ultimately stopped nilotinib, of whom 14 received an alternative TKI. Dose reduction or cessation because of VAEs did not adversely affect maintenance of major molecular response. These findings demonstrate that in contrast to other AEs, VAEs are ideally managed with nilotinib cessation because of the increased risk of additional events with its ongoing use.

scholarly journals Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia

Cancer ◽  
2021 ◽  
Author(s):  
Guillermo Montalban‐Bravo ◽  
Rashmi Kanagal‐Shamanna ◽  
Koji Sasaki ◽  
Lucia Masarova ◽  
Kiran Naqvi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
History Of ◽  
Atypical Chronic Myeloid Leukemia

scholarly journals The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

2017 ◽  
Vol 1 (13) ◽  
pp. 802-811 ◽  
Author(s):  
Lucy C. Fox ◽  
Katherine D. Cummins ◽  
Ben Costello ◽  
David Yeung ◽  
Rebecca Cleary ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Pleural Effusion ◽  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Key Points ◽  
History Of

Key PointsPrescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.

scholarly journals Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Cancer ◽  
2016 ◽  
Vol 123 (4) ◽  
pp. 609-616 ◽  
Author(s):  
Paul B. Koller ◽  
Hagop M. Kantarjian ◽  
Graciela M. Nogueras‐Gonzalez ◽  
Elias Jabbour ◽  
Srdan Verstovsek ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
History Of

Natural history of Southeast Asian Ovalocytosis during the first 3years of life

2010 ◽  
Vol 45 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Vichai Laosombat ◽  
Vip Viprakasit ◽  
Supaporn Dissaneevate ◽  
Roengsak Leetanaporn ◽  
Thirachit Chotsampancharoen ◽  
...  
Keyword(s):  
Natural History ◽  
Southeast Asian ◽  
History Of

scholarly journals The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation

Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 1483-1483
Author(s):  
Anna G. Turkina ◽  
Oleg A. Shukhov ◽  
Elza Lomaia ◽  
Elena V. Morozova ◽  
Anna Petrova ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Treatment Plan ◽  
Univariate Analysis ◽  
Hazard Ratio ◽  
Phase Iii ◽  
Molecular Response ◽  
First Results ◽  
History Of ◽  
Access Program

Abstract Background: The problem of resistance and intolerance to 2nd generation tyrosine kinase inhibitors (2G TKIs) in patients (pts) with chronic myeloid leukemia (CML) currently remains relevant. Ponatinib has demonstrated a high effectiveness and may be an option in CML pts with resistance or intolerance to available TKIs but the high incidence of vascular adverse events (AEs) limits its broad use. A STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor asciminib has demonstrated a superiority over bosutinib in CML pts previously treated with 2 or more TKIs (Phase III Study). Asciminib is available in Russia under the Managed Access Program (MAP) approved by Novartis. Aim: to present the first results of the use of asciminib in clinical practice under the MAP program in Russia. Methods: In total 46 CML pts from 3 Russian clinics were enrolled into the MAP program and received asciminib from September 2019 to June 2021 (1 pt started asciminib in a cinical trial and was transferred to MAP later). We analyzed therapy results of 32 pts who received asciminib for at least 3 months. Patient recruitment, dosing regimen, response monitoring, and toxicity control were performed according to the MAP treatment plan. Complete cytogenetic response (CCyR), major molecular response (MMR) and deep molecular response (MR4) rates were assessed by cumulative incident function (CIF). Differences between the subgroups were considered significant with p value ≤ 0.05 by the Gray's test. Results: Baseline characteristics: male: 41%; Меdian (Me) age 54 years (range 26-81); Me duration of CML before asciminib was 8 years (range 2-24); 23 pts were in chronic phase (CP) CML, 7 and 2 pts had a history of accelerated phase (AP) and blast crisis (BC), respectively, but were in a second CP at baseline. Nineteen (59%) pts had BCR-ABL mutations, 10 pts (31%) had BCR-ABLt315i clones, 7 (22%) pts had at least two mutations. Eight (25%) pts had additional chromosomal abnormalities (ACAs). Twenty one (66%) pts received ≥4 TKIs, 14 (44%) pts had a history of ponatinib treatment. Me duration of asciminib treatment at the time of analysis was 7 months (range 4-24), 4 (12.5%) pts discontinued asciminib due to lack of efficacy; all pts were alive. The initial asciminib dose was 40 BID in 22 (69%) pts and 200 mg BID in 10 (31%) pts. CCyR, MMR and MR4 at the time of analysis was achieved in 32% (8/25), 34% (10/29) and 17% (5/30) pts, respectively (considering pts without this kind of response at baseline). The 6 month CIF of CCyR, MMR and MR4 was 27%, 24% and 19%, respectively. Univariate analysis was performed in 29 pts without MMR at baseline evaluating the following factors of 6 month MMR achievement: initial dose of asciminib, CML phase, presence of BCR-ABL mutations and ACAs, best molecular response on previous TKIs, molecular response at the time of asciminib starting, history of ponatinib treatment, number of TKIs and duration of TKI therapy before asciminib. The duration and number of TKIs, the history of advanced phases, BCR-ABL kinase domain mutations and ACAs did not significantly effect on MMR rate (tab.1). BCR-ABL<1% on previous TKIs (54% vs 0%, p=0.0008, hazard ratio 20.9 (2.6-170)) and BCR-ABL<10% at the time of asciminib start (44% vs 15%, p=0.035, hazard ratio 3.8 (1.05-13.6)) were found as a predictive factors for MMR at 6 month. Fourteen (44%) of 32 pts had AEs of any grade and 7 (22%) had AEs of grade 3-4 (hematological AEs -6 (19%), non-hematological AE- 1 (3%)) (tab.2). Conclusion: Asciminib has shown promising efficacy and a good toxicity profile in a cohort of highly pre-treated CML pts and should be considered as a therapeutic option for CML pts resistant or intolerant to other TKIs. Figure 1 Figure 1. Disclosures Turkina: Bristol Myers Squibb: Speakers Bureau; Pfizer: Speakers Bureau; Pharmstandart: Speakers Bureau; Novartis Pharma: Speakers Bureau. Lomaia: Novartis: Honoraria; Pfizer: Honoraria; BMS: Honoraria; Pharmstandard: Honoraria. Petrova: Pfizer: Speakers Bureau; Novartis Pharma: Speakers Bureau. Chelysheva: Novartis Pharma: Speakers Bureau; Pharmstandart: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Pfizer: Speakers Bureau. Gurianova: Pfizer: Speakers Bureau.

Systematics and natural history of Southeast Asian Rock Geckos (genus Cnemaspis Strauch, 1887) with descriptions of eight new species from Malaysia, Thailand, and Indonesia

Zootaxa ◽  
2014 ◽  
Vol 3880 (1) ◽  
pp. 1 ◽  
Author(s):  
L. LEE GRISMER ◽  
PERRY JR L. WOOD ◽  
SHAHRUL ANUAR ◽  
AWAL RIYANTO ◽  
NORHAYATI AHMAD ◽  
...  
Keyword(s):  
New Species ◽  
Natural History ◽  
Southeast Asian ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document